Her2 targeted therapy drugs

Herceptin was the first HER2-targeted therapy for breast cancer. It is a monoclonal antibody that binds to HER2 receptors present on the surface of HER2-

Moreover, as an overexpressed cyto-membrane protein, HER2 is an attractive marker for targeted drug delivery to tumor cells. The aim of this review is to elucidate the roles of HER2 in cancer therapy and targeted drug delivery. Various therapeutic strategies targeting HER2, as well as targeted drug delivery systems will be discussed.

Anti-HER2 therapies (also called HER2 inhibitors or HER2-targeted therapies) are a class of medicines used to treat all stages of HER2-positive breast cancer.

Novel antibody drug conjugates and bispecific antibodies targeting HER2, and HER2-targeted therapies in combination with immune-checkpoint inhibition are all under investigation in clinical trials.

As a fully-validated target, HER2-targeted therapy has proven effective in breast and gastric cancers. IBI354, an anti-HER2 monoclonal

If a tumor is HER2-positive, the HER2-targeted therapy drug trastuzumab (Herceptin) is included in the chemotherapy regimen. Sometimes other drugs that target HER2 are used. Learn more about trastuzumab and other HER2-targeted therapies for early breast cancer. Learn more about other drug therapies for early breast cancer. Antibody-drug conjugates

Anti-HER2 therapies (also called HER2 inhibitors or HER2-targeted therapies) are a class of medicines used to treat all stages of HER2-positive breast cancer and certain HER2-low breast cancers.

Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.

The following targeted therapy drugs are used to treat HER2-positive breast cancer. Trastuzumab Trastuzumab (Herceptin and biosimilars ) is the most common targeted therapy drug used to treat HER2-positive breast cancer.